Clinical trial
Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With…
NCT00453986 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00453986 |
|---|---|
| Title | Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults |
| Official title | Lot-to-Lot Consistency, Non-Inferiority Versus Mencevax™ and Evaluation of the Co-Administration With Fluarix™ of GSK Biologicals' Meningococcal Vaccine GSK134612, in Healthy Subjects Aged 18 Through 55 Years of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Meningococcal |
| Intervention type | Biological |
| Interventions | Meningococcal vaccine GSK134612, Mencevax™ACWY, Fluarix™ |
| Enrollment | 1,352 |
| Start date | Apr 9, 2007 |
| Primary completion | Nov 30, 2007 |
| Completion | May 21, 2008 |
| First posted | Mar 29, 2007 |
| Last update posted | Sep 25, 2018 |
| Countries | Lebanon, Philippines |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: